The latest Business updates from the science industry
by Heather Hobbs Celebrating 70 Years of Advancing Photonics Technology
“We will continue to propose solutions to our customers’ problems and provide value that exceeds their expectations. In addition, we will continue to contribute to the world by understanding social, environmental, and human issues, and moving quickly and signifi cantly through the ‘value creation cycle’ that solves them with technology and products.” Tadashi Maruno, Representative Director, and President.
Key Milestones in Hamamatsu Photonics’ 70-Year Journey: Tadashi Maruno
Hamamatsu Photonics, a global leader in photonics technology, is proud
to announce its 70th anniversary, marking seven decades of achievements and contributions to the world of photonics.
Since its founding in 1953, Hamamatsu Photonics has made it its mission to advance science and technology by establishing photonics as a fundamental source of innovation for all its customers.
From its humble beginnings as a small factory in Hamamatsu City, Japan, the company has grown into a world-renowned provider of sophisticated detectors, sources, and imaging products ranging from components to complete systems.
• 1953: Established Hamamatsu TV Co, Ltd with the dream of linking optical technology with industry. Development of the fi rst video camera product.
• 1959: Introduction of the fi rst photomultiplier tube: a world-wide leading product. Beginning of our fi rst factories.
• 1960s: Business expansion and development. Taking up new challenges in unknown fi elds.
• 1970s: Preparation for the big leap. Laying the cornerstone for solid-state products and system products.
• 1980s: The age of photonics. Changing from Hamamatsu TV Co, Ltd to Hamamatsu Photonics KK
• 1990s: Beginning of new explorations. Stepping forward to contribute to better human life.
• 2000s: Pioneering for the next generation. Aiming at creating new industries.
• 2010s: From Hamamatsu to the world. Making further progress toward global expansion.
• 2020s: Continued growth and expansion of product portfolio in photonics.
Hamamatsu Photonics’ commitment to sustainability: Hamamatsu Photonics reaffi rms its dedication to sustainability and responsible business practices. The company actively promotes environmental conservation and social responsibility throughout its global operations, ensuring a brighter future for generations to come.
Visit the website for a detailed timeline. More information online:
ilmt.co/PL/X1od
61301pr@reply-direct.com
Expansion Underscores Exposure to Bioconjugation Solutions Market
Critical raw materials supplier Biosynth recently acquired German company celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs and polymer-based drug delivery excipients, which will now be offered to the Swiss organisation’s existing pharma and diagnostics customer base, from GMP facilities located in Berlin, Germany.
Commenting, Dr Urs Spitz, CEO and President of Biosynth, said: “celares is an established leader in bioconjugation and we are extremely excited to be acquiring such a great team of specialists.
“celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery.
“Together, we can support customers from development to commercialisation. celares is a perfect fi t for Biosynth - where chemistry meets biology.”
“We are thrilled to have joined the Biosynth group,” added Dr Ralf Kraehmer, Managing Director of celares.
“As established leaders in bioconjugation, celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward- looking technologies.
“Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development.
“We see great similarities in Biosynth with their customer led strategy and passion for the life science industry.”
More information online:
ilmt.co/PL/OpNN 61062pr@reply-direct.com
Dr Urs Spitz Funding Steers Cardiovascular Pipeline Towards Clinical Entry
Biopharma Corteria, which announced an oversubscribed €65 million ($71 million) Series A co-led by investment fi rms OrbiMed (US) and Jeito Capital (EU), will be using the funding to advance its cardiovascular pipeline into the clinic. Erez Chimovits from OrbiMed and Andreas Wallnoefer from Jeito Capital have joined Corteria’s board of Directors.
The company’s approach is centred on selecting therapeutic targets involved in the worsening and acute forms of human heart failure, as well as a stratifi cation strategy to identify specifi c subgroups that are most likely to benefi t from the treatments.
Founded in 2021 by Sanofi ’s former head of cardiovascular research, Philip Janiak and Marie-Laure Ozoux, former cardiovascular project lead, around two cardiovascular programs in-licensed from Sanofi , Corteria’s pipeline has expanded rapidly comprising three fi rst-in- class therapies that are highly differentiated as they produce multi- organ benefi ts, acting on the kidneys, the heart and the vessels.
“This fi nancing marks a major milestone in our mission to bring therapies to heart failure subpopulations with high unmet needs,” said company founder and President Philip Janiak. “We are extremely grateful to Jeito and OrbiMed as our new investors for their trust in our science and team and to our existing investors for their support and commitment since inception. We are looking forward to working all together to develop next generation
transformative therapeutics.”
Andreas Wallnoefer, Partner at Jeito Capital, said: “Despite current treatments, heart failure is a progressing disease that impacts severely the lives of many patients and remains one of the leading causes of mortality worldwide. Corteria focuses on translating important therapeutic innovation in cardiology into clinical practice. Our investment in Corteria refl ects Jeito’s commitment to address signifi cant unmet needs in the realm of cardiology. We are excited to join forces with Corteria’s dedicated team to develop a portfolio of medicines with important clinical benefi t for patients.”
“We are proud to have been involved with Corteria since its early days and impressed with the progress made to date. The company is now at a turning point of entering the clinic with its lead asset early next year and validating its unique positioning in well-defi ned heart failure subpopulations with high unmet medical needs. Kurma Partners is pleased to continue supporting the company during this key step that we hope will bring transformative clinical outcome for patients,” said Thierry Laugel, Managing Partner at Kurma Partners, and Chairman of the board of Corteria.
All existing seed investors (Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, Omnes Capital), took part in the funding round.
Philip Janiak (credit: Corteria)
More information online:
ilmt.co/PL/6qZ6 61333pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
